United States oncologists’clinical preferences regarding modes of medicinal cannabis use

作     者：Timothy S.Sannes Manan M.Nayak Stephanie Tung Peter R.Chai Miryam Yusufov Dragana Bolcic-Jankovic William F.Pirl Ilana M.Braun 

作者机构：Harvard Medical SchoolDivision of Adult Psychosocial Oncology and Palliative CareDana Farber Cancer Institute450 Brookline AvenueBostonMA 02215USA Division of Medical ToxicologyDepartment of Emergency MedicineBrigham and Women’s VC/Koch Institute for Integrated Cancer Research/Massachusetts Institute of TechnologyThe Fenway Institute 75 Francis StreetBostonMA 02115USA Center for Survey ResearchUniversity of MassachusettsBoston 100 Morrissey BlvdBostonMA 02125USA 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2021年第41卷第6期

页      面：528-531页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：NIDA NIH HHS [K23 DA044874] Funding Source: Medline 

主　　题：cancer clinical medicinal 

摘      要：Dear Editor,Almost every state in the United States with a comprehensive medicinal cannabis(MC)law identifies cancer as a qualifying condition for MC use[1,2].A growing body of scientific literature indicates that cancer patients use MC for both symptom management(e.g.,pain,low appetite,fatigue,mood disturbance)and cancer-directed therapy[3,4].